Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2021-04-12 Major Shareholding Noti…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (Cha Kwang-yul) and special related parties, including share purchases and collateral contract extensions. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2021-04-12 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding the scheduling and details of an upcoming Investor Relations (IR) meeting (기업설명회). It provides the date, time, location, purpose, and agenda items for the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it fits the regulatory requirement for disclosing investor meetings, it is classified as a Regulatory Filing (RNS).
2021-04-06 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow) scheduled for 2021-03-30. It provides details such as the date, location, purpose, and method of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2021-03-29 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend status, director appointments, and business purpose changes. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which reports the official outcomes of shareholder votes at a general meeting.
2021-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment, dismissal, or resignation of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This type of disclosure specifically pertains to changes in the company's board of directors or senior management, which falls under the 'Board/Management Information' category.
2021-03-26 Korean
전환가액의조정(제6회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (6th series) issued by Cha Biotech. It details the change in conversion price due to a decline in market price, the resulting change in the number of convertible shares, and the calculation methodology. This falls under capital structure changes related to convertible debt instruments, which is best classified as a Capital/Financing Update (CAP).
2021-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.